Analyst Reco. Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
11.71 ^USD	+5.40%		+5.88%	-22.71%

11/04	Zentalis Pharmaceuticals, Inc. Announces Executive Changes	CI
11/04	Zentalis Pharmaceuticals, Inc. Announces CFO Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating	28/02	MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	23/01	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating	28/11	MT
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38	08/11	MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating	07/11	MT
HC Wainwright Lowers Price Target on Zentalis Pharmaceuticals to $46 From $55, Maintains Buy Rating	07/11	MT
Morgan Stanley Adjusts Price Target on Zentalis Pharmaceuticals to $38 From $55, Maintains Overweight Rating	07/11	MT
Wells Fargo Adjusts Price Target on Zentalis Pharmaceuticals to $50 From $51, Maintains Overweight Rating	10/23/10	MT
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $50 From $45, Maintains Buy Rating	07/23/07	MT
Wedbush Raises Zentalis Pharmaceuticals' Price Target to $38 From $31, Says Topline Azeno Combo Data Impresses; Keeps Outperform Rating	26/23/26	MT
Jefferies Adjusts Price Target on Zentalis Pharmaceuticals to $70 From $120, Maintains Buy Rating	19/23/19	MT
Wedbush Trims Zentalis Pharmaceuticals' Price Target to $31 From $33, Adjusts Launch Timing Assumptions; Keeps Outperform Rating	11/23/11	MT
Wedbush Lifts Zentalis Pharmaceuticals' PT to $33 From $32, Sees Number of Compelling Value Opportunities Ahead; Keeps Outperform Rating	02/23/02	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $52 From $91, Maintains Buy Rating	21/22/21	MT
UBS Adjusts Zentalis Pharmaceuticals Price Target to $52 From $91, Maintains Buy Rating	18/22/18	MT
Wedbush Lowers Price Target on Zentalis Pharmaceuticals to $32 From $51, Keeps Outperform Rating	14/22/14	MT
SVB Securities Trims Price Target on Zentalis Pharmaceuticals to $27 From $42, Affirms Outperform Rating	11/22/11	MT
Morgan Stanley Cuts Price Target on Zentalis Pharmaceuticals to $55 From $60, Keeps Overweight Rating	11/22/11	MT
Guggenheim Lowers Price Target on Zentalis Pharmaceuticals to $28 From $55, Maintains Buy Rating	11/22/11	MT
Oppenheimer Adjusts Zentalis Pharmaceuticals Price Target to $50 From $80, Maintains Outperform Rating	10/22/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Analyst Reco.

Filters